

Electronic Supplementary Information

*of*

**A Modular Theranostic Platform for Tumor Therapy and  
its Metabolic Studies**

Ke Li<sup>§</sup>, Jiang-Lan Li<sup>§</sup>, Di-Wei Zheng, Xuan Zeng,<sup>\*</sup> Chuan-Jun Liu<sup>\*</sup>, and Xian-Zheng  
Zhang<sup>\*</sup>

Key Laboratory of Biomedical Polymers of Ministry of Education & Department of  
Chemistry, Wuhan University, Wuhan 430072, P. R. China

<sup>\*</sup>Corresponding author. Tel.: +86 27 6875 5993; Fax: +86 27 6875 4509.


E-mails: zeng\_xuan@163.com (X. Zeng), cjliu@whu.edu.cn (C.J. Liu), xz-  
zhang@whu.edu.cn (X.Z. Zhang)

<sup>§</sup>These authors contributed equally to this work.


**Materials:** *p*-methyl benzene sulfonic chloride (*p*-TsCl), dimethyl formamide (DMF),  $\beta$ -cyclodextrin ( $\beta$ -CD), sodium hydroxide (NaOH), acetone, hydrochloric acid (HCl), methanol, trimethylamine (TEA), ethylsilicate (TEOS), toluene, ethyl acetate, hexadecyl trimethyl ammonium bromide (CTAB), and hydrofluoric acid were purchased from Shanghai Reagent Chemical Co. (China). Ethanediamine (EDA), amidotrizoic acid, tetrabutylammonium iodide, 1H-Benzimidazole-5-carboxylic acid, 3-chloropropyltriethoxysilane, ferrocenecarboxylic acid (FA), diamine polyethylene glycol ( $M_w=1000$ ), and ethylene diamine tetraacetic acid (EDTA) were purchased from Aladdin Industrial Corporation. Tri-tert-butyl 1,4,7,10-Tetraazacyclododecane-1,4,7,10-triacetate (t-Bu-DOTA) was purchased from TCI (Shanghai) Development Co., Ltd. *N,N*-Diisopropylethylamine (DIEA), *N*-Hydroxybenzotriazole (Hobt), and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (Pybop) were purchased from Glibiochem (Shanghai) Ltd. DMF, TEA, and toluene were redistilled before used. Doxorubicin hydrochloride (DOX) was purchased from Zhejiang Hisun Pharmaceutical Co. (China). Other reagents were purchased from Shanghai Reagent Chemical Co., Ltd (China) and used as received.

**Characterizations:** Transmission electron microscopy (TEM) images were carried out on a JEM-2100 (JEOL) transmission electron microscope. Confocal microscopy images were performed on a C1-Si (Nikon) confocal laser scan microscope (CLSM). Zeta potential was determined by a zeta sizer (Malvern). Fourier transform-infrared spectroscopy (FT-IR) was recorded on KBr pellets by means of a Spectrum Two FT-IR Spectrophotometer (Perkin-Elmer). The fluorescence of DOX was detected using a fluorescence spectrophotometer photometer (Perkin-Elmer).  $^1\text{H}$ -NMR spectra were obtained on a Mercury VX-300 spectrometer (Varian) with  $\text{D}_2\text{O}$  and  $\text{DMSO-d}_6$  as the solvent. Image acquisition of the *in vivo* drug distribution was performed by a small


animals living imaging system (maestro). *In vivo*  $^1\text{H}$ -MRS was preferred on a 7.0 T magnetic resonance imaging equipment.




**Fig. S1.** BET nitrogen adsorption/desorption isotherms (a) and BJH pore size distribution (b) of MSN nanoparticles.



**Fig. S2.** FT-IR spectrum of modified MSN(I: CTAB@MSN; II: MSN; III: Cl-MSN; IV: Bz-MSN; V: PEG-Bz-MSN; VI: Fc-PEG-Bz-MSN; VII: β-CD-MSN).



**Fig. S3.** H&E staining of tissues treated with (a) PBS, (b) DOX and (c) DOX@FAMSN. Image 1: heart; Image 2: liver; Image 3: spleen; Image 4: lung; Image 5: kidney ( $\times 200$ ). Scale bar: 100  $\mu\text{m}$ .



**Figure S4.** (a) Fluorescence field for heart (as circled), lung, liver, spleen, tumor and kidney. (b) Bright field for heart, lung, liver, spleen, tumor and kidney.